Conclusions

The last few years have been filled with tremendous excitement as the dramatic activity of imatinib has been demonstrated in clinical trials. The clinical development of imatinib has shown that a combination of the right drug with the appropriate target disease and patient population can reveal the true potential of such targeted agents.

Acknowledgements Dr. Druker's laboratory is supported by the Howard Hughes Medical Institute and grants from the National Cancer Institute, The Leukemia and Lymphoma Society, the Burroughs Wellcome Fund, the T.J. Martell Foundation, and the Doris Duke Charitable Foundation.

Was this article helpful?

0 0

Post a comment